Welcome to our dedicated page for Rapport Therapeutics SEC filings (Ticker: RAPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Rapport Therapeutics, Inc. (Nasdaq: RAPP) provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. Rapport’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market under the symbol RAPP, so its filings offer detailed information on its precision neuroscience business and capital markets activity.
Through this page, readers can review Form 10-K and Form 10-Q reports (when filed) for discussions of Rapport’s RAP technology platform, the development of RAP-219 for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain, and additional programs in chronic pain, migraine, and hearing or vestibular disorders. These periodic reports also describe risk factors, research and development expenses, and other elements of the company’s operating profile.
Frequent Form 8-K filings from RAPP document material events such as positive Phase 2a trial results for RAP-219 in focal onset seizures, new data analyses presented at scientific meetings, public offerings of common stock under an effective shelf registration statement on Form S-3, and quarterly financial results and business updates. Some 8-Ks also summarize regulatory developments, including clinical holds, end-of-Phase 2 planning, and changes to at-the-market sales arrangements.
Investors can also use this page to locate information related to shareholder meetings and voting outcomes, as disclosed in 8-K items covering submissions of matters to a vote of security holders. Insider transaction reports on Form 4, when available, complement these filings by showing equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight clinical and financial milestones, and make it easier to understand how new disclosures may relate to Rapport’s RAP-219 program and broader precision neuroscience pipeline. Real-time updates from EDGAR help ensure that new RAPP filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are quickly accessible in one place.
Rapport Therapeutics (RAPP) filed its Q3 2025 10‑Q, reporting a net loss of
The balance sheet strengthened following a September follow‑on equity raise. As of September 30, cash and cash equivalents were
In September 2025, the company completed an underwritten public offering of 11,057,692 shares at
Rapport Therapeutics (RAPP) furnished an update on its financial results and business highlights for the quarter ended September 30, 2025. The details are provided in a press release attached as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed under Section 18 of the Exchange Act. RAPP’s common stock trades on The Nasdaq Global Market.
Rapport Therapeutics (RAPP): Form 4 insider sale. On 10/15/2025, the Chief Scientific Officer sold 7,418 shares at a weighted average price of $25.7329 and 1,082 shares at a weighted average price of $26.1641. Sales occurred in multiple trades within disclosed ranges.
Following these transactions, the officer directly holds 409,642 shares. The trades were executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.
Rapport Therapeutics (RAPP) — insider trading report: On 10/15/2025, the company’s Chief Executive Officer and Director executed multiple open‑market sales under Rule 10b5‑1 trading plans adopted on December 12, 2024. Reported transactions included 4,647 shares at a weighted average price of $25.724 and 1,186 shares at $26.1392. Trust-related sales included 4,328 shares at $25.746 and 755 shares at $26.1721.
After these transactions, the reporting person beneficially owned 579,579 shares directly. Indirect holdings reported were 41,061 shares held by the Dorothy Ceesay Irrevocable Trust and 81,729 shares held by the Ceesay Family Irrevocable Trust.
Ceesay Abraham, who is listed as both Chief Executive Officer and a director of Rapport Therapeutics, Inc. (RAPP), reported multiple dispositions of the company’s common stock on 09/17/2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. The Form 4 lists four disposition entries: 39,435 shares at a weighted-average price of $26.299, 1,400 shares at $26.8745, 34,885 shares at $26.3019 and 700 shares at $27.0429. The filing shows resulting beneficial ownership figures on each line, including direct holdings of 585,412 and 586,812 shares on certain lines and indirect holdings held by the Dorothy Ceesay Irrevocable Trust and the Ceesay Family Irrevocable Trust (listed as 46,844 I, 46,144 I and 81,729 I). Explanatory notes disclose price ranges for the multiple transactions and that the reporting person disclaims beneficial ownership of trust-held shares except to the extent of any pecuniary interest.
Rapport Therapeutics (RAPP) Amendment No. 1 to Schedule 13D reports that a Sofinnova group of entities and individuals collectively now beneficially own 1,863,327 shares of Common Stock, representing 4.0% of the outstanding shares based on 46,113,062 shares outstanding after the offering. The filing explains that Sofinnova Venture Partners XI originally acquired 11,924,138 Series B shares for $19,999,999 which converted into Common Stock at a 1-for-8.5648 ratio at the IPO. SVP XI separately purchased 470,589 shares in a private placement for $8,000,013 at $17.00 per share. The reporting persons state they ceased to be beneficial owners of more than 5% due to dilution from issuer share sales and confirm lock-up, investor rights and registration arrangements. The filing lists additional small open-market purchases and distributions and discloses a director stock option of 21,850 shares at $10.95 (vesting by June 17, 2026).
Rapport Therapeutics, Inc. (RAPP) filed a Form 144 reporting a proposed sale of 52,501 common shares, representing part of its outstanding stock, with an aggregate market value of $1,375,001.19. The sale is to be handled through Morgan Stanley Smith Barney LLC on NASDAQ with an approximate sale date of 09/17/2025. The shares were acquired on 12/02/2022 under an RSA from the issuer. The filer reports no securities sold in the past three months and provides the standard attestation about material nonpublic information.
Form 144 notice for Rapport Therapeutics, Inc. (RAPP) reports a proposed sale of 45,751 common shares through Morgan Stanley Smith Barney LLC on 09/17/2025 on NASDAQ with an aggregate market value of $1,198,218.69. The shares were acquired from the issuer under an RSA on 06/10/2024, and no securities were reported sold in the prior three months by the selling person. The filing includes the seller's representation that they are not aware of any undisclosed material adverse information about the issuer. This notice provides the broker, share count, acquisition details, planned sale date, and aggregate value as required under Rule 144.
David Bredt, Chief Scientific Officer of Rapport Therapeutics, Inc. (RAPP), reported sales of company common stock on 09/15/2025. The Form 4 shows two separate sale entries executed under a Rule 10b5-1 trading plan adopted on December 12, 2024: 5,098 shares sold at a weighted-average price of $23.8841 and 3,402 shares sold at a weighted-average price of $24.6583. The filing lists beneficial ownership amounts following the transactions as 421,544 and 418,142 shares respectively. The report was signed by an attorney-in-fact on behalf of the reporting person on 09/17/2025.
Rapport Therapeutics director Reid M. Huber purchased 20,400 shares of RAPP common stock on 09/12/2025 at a weighted-average price of $24.4791 per share, with transaction prices ranging from $24.23 to $24.50. After the purchase Huber beneficially owns 20,400 shares directly. No derivative securities were reported. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/15/2025. The filer notes the reported price is a weighted average and offers to provide a breakdown of the individual trade prices on request.